Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Background: Upfront cytoreductive nephrectomy (CN) is no longer the standard of care for patients with metastastic renal cell carcinoma (mRCC) with intermediate or poor prognosis according to the International mRCC Database Consortium categories. Objective: To investigate indications for CN followin...

Full description

Bibliographic Details
Main Authors: Elisabeth E. Fransen van de Putte, Luna van den Brink, Mohamed A. Mansour, Johannes C. van der Mijn, Sofie Wilgenhof, Johannes V. van Thienen, John B.A.G. Haanen, Ekaterini Boleti, Thomas Powles, Patricia J. Zondervan, Niels M. Graafland, Axel Bex
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:European Urology Open Science
Subjects:
Cytoreductive
Ipilimumab
Nephrectomy
Nivolumab
Indications
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168323003798

Internet

http://www.sciencedirect.com/science/article/pii/S2666168323003798

Similar Items